TechsoMed

Company profile

About TechsoMed

TechsoMed is a global medical imaging software company specializing in AI-powered image-guided ablation therapy (IGAT) systems for cancer treatment. Founded in 2015 and headquartered in Or-yehuda, Israel, the company addresses critical challenges in minimally invasive oncology procedures where more than half of treatments fail to completely eliminate cancerous tissue. The company's flagship BioTraceIO360 platform represents the world's first FDA-cleared software for tissue response prediction in tumor ablation. The platform compresses thousands of imaging frames into one actionable interface, providing physicians with 360-degree intelligent visualization throughout the entire ablation workflow—from pre-procedure planning through real-time monitoring to post-treatment verification. BioTrace delivers risk-aware 3D modeling, smarter needle path planning, real-time margin visualization, in-procedure tumor coverage assessment, and predictive tissue response analysis. The system is vendor-agnostic and integrates with standard medical imaging modalities including ultrasound, CT, and MRI. TechsoMed has received multiple FDA clearances, including De Novo clearance for tissue response prediction and 510(k) clearances for liver and kidney ablation applications. The company operates subsidiaries in Germany (in partnership with Fraunhofer Mevis) and Japan, and has established strategic partnerships with major healthcare technology companies including Medtronic, GE HealthCare, and Lenovo. TechsoMed's mission extends beyond current applications, with a roadmap targeting expansion into embolization therapy, radiation therapy, cryoablation, pain management, and cardiovascular ablation to make intelligent minimally invasive solutions accessible to patients everywhere.

Company description · TechsoMed official website